Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.

0
3


Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment.

Germantown’s Precigen Inc. has earned orphan drug status from the Food and Drug Administration for its therapy for relapsed or refractory acute myeloid leukemia, a form of cancer in the blood and bone marrow, in cases that have either come back or failed to respond to past treatment. The company …

Related Links:

Conclusion


A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all…

Source: Fight Aging!Category: Research Authors: Tags: Newsletters Source Type: blogs

Authors: Kim DY, Lee S, Kim DY, Lee JY
Abstract
Murine models have become powerful tools in leukemia research for investigating interactions between blast cells niche factors. In the tumor microenvironment, immune cells are one of the most important niche factors, capable of mounting dynamic innate or adoptive responses against leukemic cells. Acute myeloid leukemia (AML) is a systemic cancer accompanied by immune disruption. In order to exploit the enhanced activity of immune cells in AML treatment, the use of syngeneic mouse models is necessary. Studies of crosstalk between cancer blast cells and immune cells in …

uccisano
Venditti

Acute myeloid leukemia (AML), with an incidence increasing with age, is the most common acute leukemia in adults. Concurrent comorbidities, mild to severe organ dysfunctions, and low performance status (PS) are frequently found in older patients at the onset, conditioning treatment choice and crucially influencing the outcome. Although anthracyclines plus cytarabine-based chemotherapy, also called “7 + 3” regimen, remains the standard of care in young adults, its use in patients older than 65 years should be reserved to selected cases because of higher incidence of toxicity. The…

Source: CancersCategory: Cancer & Oncology Authors: Tags: Review Source Type: research

PMID: 31896685 [PubMed – as supplied by publisher]

Source: HaematologicaCategory: Hematology Authors: Tags: Haematologica Source Type: research

Publication date: February 2020Source: Biomedicine &Pharmacotherapy, Volume 122Author(s): Liangyan Zhang, Zibin Bu, Juan Shen, Liping Shang, Yuanyuan Chen, Yan WangAbstractFLT3-ITD+ acute myeloid leukemia (AML) is an important subtype of AML, accounting for approximately 25 % of all AML cases in the world. Recently, increasing evidence has shown that circular RNAs (circRNAs) can act as effective biomarkers of various human cancers. However, the roles of circRNAs in AML remain largely unclear. In the present study, circ_0000370 was found to be significantly increased in FLT3-ITD+ AML and was demonstrated to act as an on…

Conclusion


A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all…

Source: Fight Aging!Category: Research Authors: Tags: Of Interest Source Type: blogs

Contributors : Anuhar Chaturvedi ; Michael HeuserSeries Type : Expression profiling by arrayOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 months, suggesting that IDH1 inhibitors shoul…

Source: GEO: Gene Expression OmnibusCategory: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research

rian

Acute myeloid leukemia (AML) is an aggressive hematological disorder mainly affecting people of older age. AML initiation is primarily attributed to mutations in crucial cellular regulators such as epigenetic factors, transcription factors, and signaling genes. AML’s aggressiveness and responsiveness to treatment depends on the specific cell type where leukemia first arose. Aged hematopoietic cells are often genetically and/or epigenetically altered and, therefore, present with a completely different cellular context for AML development compared to young cells. In this review, we summarize key aspects of…

Source: CancersCategory: Cancer & Oncology Authors: Tags: Review Source Type: research

ze
Arnaud Pigneux
Norbert Vey
Karine Celli-Lebras
Christine Terré
Claude Preudhomme
Hervé Dombret

Acute myeloid leukemia (AML) encompasses heterogeneous entities with dismal outcomes. Intermediate and unfavorable-risk AML represent the most difficult-to-treat entities. We recently reported the benefit of the clofarabine-based consolidation (CLARA) regimen compared to the standard high-dose cytarabine (HDAC) regimen in younger AML patients. Here, we aimed at assessing the clinical significance of single-nucleotide polymorphism (SNP)-array alterations and their interactions with chemotherapy reg…

Source: CancersCategory: Cancer & Oncology Authors: Tags: Brief Report Source Type: research



Source link